ANDA 75776, held by Chartwell RX. Hydrochlorothiazide; Lisinopril.
As of Nov 20, 2026, ANDA 75776 (Lisinopril and Hydrochlorothiazide), held by Chartwell RX, was first approved by FDA on Jul 1, 2002, with 15 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2002 | Original application | Approved | None posted |
| Lisinopril and Hydrochlorothiazide12.5MG;10MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Discontinued |
| Lisinopril and Hydrochlorothiazide12.5MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Discontinued |
| Lisinopril and Hydrochlorothiazide25MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Discontinued |
| Aug 20, 2020 | Supplement 44Labeling · Standard review | Approved | None posted |
| Dec 17, 2019 | Supplement 40Labeling · Standard review | Approved | None posted |
| Dec 17, 2019 | Supplement 42Labeling · Standard review | Approved | None posted |
| Dec 17, 2019 | Supplement 43Labeling · Standard review | Approved | None posted |
| Feb 28, 2014 | Supplement 18Labeling | Approved | None posted |
| Feb 26, 2014 | Supplement 38Labeling · Standard review | Approved | None posted |
| Feb 26, 2014 | Supplement 39Labeling · Standard review | Approved | None posted |
| Aug 1, 2013 | Supplement 32Labeling | Approved | None posted |
| Aug 1, 2013 | Supplement 34Labeling | Approved | None posted |
| Aug 1, 2013 | Supplement 35Labeling · Standard review | Approved | None posted |
| Aug 1, 2013 | Supplement 36Labeling · Standard review | Approved | None posted |
| Aug 1, 2013 | Supplement 37Labeling · Standard review | Approved | None posted |
| Feb 1, 2010 | Supplement 28Labeling | Approved | None posted |
| Jul 10, 2009 | Supplement 22Labeling | Approved | None posted |
| Oct 26, 2004 | Supplement 8Labeling | Approved | None posted |
| Jul 1, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters